Patients may slowly develop increased brown pigmentation of the iris. This change may not be noticeable for months to years (see Warnings). Iris pigmentation changes may be more noticeable in patients with mixed coloured irides, i.e., blue-brown, grey-brown, yellow brown and green-brown; however, it has also been observed in patients with brown eyes. The colour change is believed to be due to increased melanin content in the stromal melanocytes of the iris. The exact mechanism of action is unknown at this time. Typically the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. Until more information about increased brown pigmentation is available, patients should be examined regularly and depending on the situation, treatment may be stopped if increased pigmentation ensues. Owing to systemic absorption, the side-effects associated with beta blockers are likely to occur. Caution should be exercised in patients with bronchial asthma, COPD or CHF. TRAVOPROSTIN-T should be used with caution in patients with active intraocular inflammation (iritis/uveitis). Macular oedema, including cystoid macular oedema, has been reported during treatment with prostaglandin F2alpha analogues. These reports have mainly occurred in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema. TRAVOPROSTIN-T should be used with caution in these patients. TRAVOPROSTIN-T has not been evaluated for the treatment of angle closure, inflammatory or neovascular glaucoma. TRAVOPROSTIN-T has not been studied in patients with renal or hepatic impairment and should be used with caution in such patients. TRAVOPROSTIN-T should not be administered while wearing contact lenses. Contact lenses should be removed prior to the administration of the solution. Lenses may be reinserted 15 minutes following administration of TRAVOPROSTIN-T.